Thanks for your generous work on this hobbes.
In your blog you say the following about realising maximum cash as quickly as possible:- Actively seeking a merger of the CD Funds with another listed or unlisted fund (e.g. Pengana's PE1).
- To the extent possible, seeking the CD Fund General Partners to more actively pursue secondary transactions at reasonable values to quicken portfolio realisation.
- Pursuing more efficient distribution of available cash and making overall cash positions more transparent at least each quarter. For example, based on the 31 Mar 2023 annual report, CD2 has over 50 cents in cash but no distributions have been announced or foreshadowed.
Is the aim of the first point to close the NAV discount?
And can you say a little more about the second point? Presumably, CD Fund investments are closed / realised at a time that represents best value to shareholders. Are you suggesting this may not be the case (apologies if I am misunderstanding)?
Is the general proposition that while there is nothing to suggest K2 would not do a reasonable job for shareholders, the vote should be used as an opportunity to extract undertakings that assist the shareholders?
- Forums
- ASX - By Stock
- CD3
- Why CD Fund investors should vote against KAM taking over as responsible entity
CD3
cd private equity fund iii
Add to My Watchlist
0.00%
!
$1.18

Why CD Fund investors should vote against KAM taking over as responsible entity, page-4
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$1.18 |
Change
0.000(0.00%) |
Mkt cap ! $84.99M |
Open | High | Low | Value | Volume |
$1.18 | $1.19 | $1.18 | $125.4K | 106.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 21248 | $1.15 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.22 | 5151 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 21248 | 1.150 |
1 | 1854 | 1.125 |
2 | 10000 | 1.120 |
1 | 6144 | 1.110 |
1 | 2 | 1.090 |
Price($) | Vol. | No. |
---|---|---|
1.220 | 5151 | 1 |
1.240 | 2546 | 1 |
1.250 | 21450 | 1 |
1.320 | 63095 | 1 |
1.330 | 62500 | 1 |
Last trade - 15.31pm 26/06/2025 (20 minute delay) ? |
Featured News
CD3 (ASX) Chart |
The Watchlist
PTX
PRESCIENT THERAPEUTICS LIMITED
James McDonnell, CEO
James McDonnell
CEO
Previous Video
Next Video
SPONSORED BY The Market Online